{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-088353","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.527179+00:00","generated_at":"2026-05-31T10:02:29.812169+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TELA Bio Q2 2024 revenue $16.1M (+11% YoY), net loss $12.6M; reiterates FY guidance","bullets":["Revenue $16.1M, +11% YoY; net loss $12.6M vs $10.8M loss in Q2 2023.","FY 2024 revenue guidance reiterated at $74.5M-$76.5M (27%-31% YoY growth).","Appointed Greg Firestone as CCO on May 20 to boost commercial productivity.","Launched robotically compatible OviTex IHR for inguinal hernia market in U.S.","Expects $3M-$7M in total NIVIS revenue share payments over next eight quarters starting Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-088353","json":"https://secwatch.observer/filing/0001104659-24-088353.json","markdown":"https://secwatch.observer/filing/0001104659-24-088353.md","text":"https://secwatch.observer/filing/0001104659-24-088353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465924088353/0001104659-24-088353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465924088353/tm2421368d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:02:29.812169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}